Nurix Therapeutics is trading at $15.31, down 4.01%, amid broad-market weakness. - The November 5 decline coincides with major indexes and biotech stocks moving lower. - Sanofi’s decision to terminate development of SAR448272 removes future milestones and royalties; the news was linked to the prior session’s steep decline. - No separate November 5 company announcement explaining the additional drop was identified.